KVUE Gains U.S. FDA Approval for Tylenol‑Naproxen OTC Combo as Merger Progresses

Kenvue Inc. (NYSE: KVUE) secured U.S. Food and Drug Administration approval for its first over‑the‑counter fixed‑dose Tylenol (acetaminophen) and naproxen combination in July 2026. The approval includes a three‑year exclusivity period, marking a material innovation for its pain relief portfolio and providing potential strategic advantage for the company.

The FDA approval, announced by Reuters on July 24, 2026, represents the first OTC combination of acetaminophen and naproxen for 12‑hour pain relief and confers valuable market protection over the three‑year exclusivity window. This development is expected to support Kenvue’s performance in the Pain Care category. Reuters reported this approval along with related margin dynamics in its coverage. 

At the same time, Kenvue reported its fiscal second‑quarter 2026 results in early August. Net sales rose 3.0% year‑over‑year to $3.96 billion, with organic sales up 1.6%. Net income increased to $456 million from $420 million a year earlier, while diluted earnings per share climbed 9% to $0.24; adjusted diluted EPS rose to $0.31. All three of Kenvue’s segments posted net‑sales growth, led by a 5.1% increase in its Skin Health & Beauty segment. The company attributed much of its Q2 momentum to operational efficiency, segment strength, and innovation—specifically highlighting the approved Tylenol‑naproxen combination. Reuters also noted that due to the pending Kimberly‑Clark merger, Kenvue did not provide forward guidance or host an earnings call. 

These developments come amid ongoing activity related to Kenvue’s pending combination with Kimberly‑Clark, expected to close in the fourth quarter of 2026. The merger is being advanced through financing and regulatory steps, according to both SEC filings and financial reporting. 

Why this matters:

• The FDA approval grants Kenvue exclusive rights to market the first OTC Tylenol‑naproxen combo, potentially enhancing its pain relief offerings and revenue in this category.
• Strong Q2 results underscore the company’s operational resilience and highlight innovation as a growth driver, even as macroeconomic and regulatory headwinds persist.
• The merger’s advancing timeline adds strategic uncertainty but also prospects for scale—an important factor for investors evaluating KVUE’s near‑term outlook.

Investors should monitor U.S. launch timelines and initial traction of the new OTC pain product, along with updates on the Kimberly‑Clark merger and any guidance restored post‑transaction.

Note: As of October 7, 2026, KVUE is trading at $17.53, reflecting a –0.51% change that day.